Search Results - "TORPAI, Raimund"

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis

    Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis by HEYMANS, Stephane, PAUSCHINGER, Matthias, PADALKO, Elisabeth, NEYTS, Johan, SCHULTHEISS, Heinz-Peter, VAN DE WERF, Frans, CARMELIET, Peter, PINTO, Yigal M, DE PALMA, Armando, KALLWELLIS-OPARA, Angela, RUTSCHOW, Susanne, SWINNEN, Melissa, VANHOUTTE, Davy, FANGYE GAO, TORPAI, Raimund, BAKER, Andrew H

    Published in Circulation (New York, N.Y.) (08-08-2006)
    “…Acute viral myocarditis is an important cause of cardiac failure in young adults for which there is no effective treatment apart from general heart failure…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14

    Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability of the recombinant Bacillus Calmette Guérin VPM1002BC in patients with non-muscle invasive bladder cancer recurrence after BCG induction with or without BCG maintenance therapy – SAKK 06/14 by Rentsch, Cyrill A, Thalmann, George N, Lucca, Ilaria, Kwiatkowski, Maciej, Wirth, Grégory J, Strebel, Räto T, Daniel, Engeler, Augusto, Pedrazzini, Clemens, Hüttenbrink, Wolfgang, Schultze-Seemann, Raimund, Torpai, Lukas, Bubendorf, Andreas, Wicki, Beat, Roth, Piet, Bosshard, Heike, Püschel, Daniel, Boll, Lukas, Hefermehl, Florian, Roghmann, Michael, Gierth, Karin, Ribi, Simon, Schäfer, Stefanie, Hayoz

    Published in Urologic oncology (01-12-2020)
    “…VPM1002BC is a genetically modified Mycobacterium bovis Bacillus Calmette Guérin (BCG) strain with potentially improved immunogenicity and attenuation. Here,…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14

    A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14 by Rentsch, Cyrill A., Thalmann, George N., Lucca, Ilaria, Kwiatkowski, Maciej, Wirth, Grégory J., Strebel, Räto T., Engeler, Daniel, Pedrazzini, Augusto, Hüttenbrink, Clemens, Schultze-Seemann, Wolfgang, Torpai, Raimund, Bubendorf, Lukas, Wicki, Andreas, Roth, Beat, Bosshard, Piet, Püschel, Heike, Boll, Daniel T., Hefermehl, Lukas, Roghmann, Florian, Gierth, Michael, Ribi, Karin, Schäfer, Simon, Hayoz, Stefanie

    Published in European urology oncology (01-04-2022)
    “…Intravesical therapy with the recombinant bacillus Calmette-Guérin (BCG) strain VPM1102BC is safe and well tolerated and maintains quality of life in 70% of…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: